Sort by
Refine Your Search
-
to lead first-author publications, develop novel methodologies, and present at international meetings. About you You will hold (or be near completion of) a PhD in cancer biology, stem cell biology, or a
-
mechanistic insights and translational applications, with the chance to lead high-profile publications. About you You will hold (or be close to completing) a PhD in molecular biology, genomics, bioinformatics
-
. About you You will hold (or close to completion) a PhD/DPhil in Bioinformatics, Statistics, Mathematics, or microbiology with proven and demonstrable analytical skills, including in the analysis
-
candidate will hold a DPhil/PhD/MD (or be near completion) or equivalent, have a proven track record in biochemical assays and imaging, and have the ability to work collaboratively within a team. It would be
-
. You should have GMC registration, MRCP (or equivalent) and higher degree (DPhil/PhD) as well as CCT (or equivalent) in acute general/internal medicine, infectious disease/microbiology. Application
-
the group and communicating our research; and generating new research and grant opportunities. It is essential that the post-holder has a doctoral degree (PhD or DPhil) in physics, engineering, or another
-
The successful candidate will hold a relevant PhD/DPhil and a good first degree in the curriculum subject, along with a UK teaching qualification or equivalent. They will have: • Significant experience
-
by acting as a Tutorial Fellow at either St. Catherine’s or St. Peter’s College. You should have a higher degree (DPhil/PhD) and postdoctoral experience in a relevant biologically-related science; an
-
that fosters regular discussion and interdisciplinary exchange. We welcome applications from highly motivated, creative individuals with a deep interest in immunology and a strong publication record. A PhD (or
-
hold a PhD/DPhil (or close to completion) in immunology or a related field, alongside demonstrable experience in culturing and performing in vitro assays with T cells, and generating in vitro CD4+ T cell